GoodRx Holdings, Inc. (NASDAQ:GDRX), a company specializing in computer processing and data preparation with a market capitalization of $1.77 billion, announced today the appointment of Wendy Barnes as its new Chief Executive Officer and President, effective January 1, 2025.
According to InvestingPro analysis, the company appears undervalued at its current price of $4.59, maintaining impressive gross profit margins of 94%. Barnes, who will also join the company's Board of Directors as a Class I director, brings extensive leadership experience from her tenure in the healthcare industry.
Barnes succeeds Scott Wagner, who has served as Interim CEO. Her appointment is part of a planned leadership transition by GoodRx's Board of Directors. Prior to joining GoodRx, Barnes was the CEO of RxBenefits, Inc., and held various roles at Express Scripts Holding Company, including President. The leadership change comes as GoodRx maintains a strong financial position with liquid assets exceeding short-term obligations and operates with a moderate level of debt.
Under the terms of her employment agreement, Barnes will receive an annual base salary of $825,000 and is eligible for an annual cash incentive bonus targeted at 100% of her base salary, contingent upon the achievement of performance goals. She will also receive a one-time signing bonus of $550,000.
Furthermore, Barnes will be granted equity awards under the company's 2020 Incentive Award Plan, including restricted stock units valued at $11 million and stock options valued at $9 million, which are subject to vesting conditions.
If Barnes' employment is terminated under certain conditions, she will be eligible for severance payments and benefits, including a continuation of her base salary for up to 18 months and company-paid COBRA premiums.
GoodRx's decision to bring Barnes on board reflects the company's commitment to strong leadership and is expected to guide the company through its next phase of growth. The specifics of Barnes' role and the strategic direction she will take the company remain to be seen as she takes the helm in the new year.
In other recent news, GoodRx Holdings Inc. has announced the appointment of Wendy Barnes as its new CEO, effective from January 1, 2025. Barnes, with over three decades of leadership experience in the pharmacy and medical benefit sectors, will transition from her current role as CEO of RxBenefits. In her new role at GoodRx, she will focus on strategic initiatives to enhance the company's platform and improve accessibility and affordability in healthcare.
On the financial front, GoodRx reported an 8% year-over-year increase in total revenue in the third quarter, reaching $195.3 million. The company's adjusted EBITDA also grew by 21%, with a margin of 33.3%. Despite the challenges in the retail pharmacy sector, GoodRx projects around $200 million in revenue for Q4 and forecasts single-digit growth for 2025.
However, Mizuho (NYSE:MFG) initiated coverage on GoodRx with a Neutral rating, citing concerns about the impact of recent store closures by large retail drug chains on the company's performance. Mizuho's projections for GoodRx's 2026 revenue stand at $860 million, falling short of the company's target of around $1 billion. The firm's earnings per share estimate for GoodRx in 2026 is also lower than the Street's expectation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.